Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-directacting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

Ítems similars

• Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
  per: Chung-Feng Huang, et al.
  Publicat: (2024-07-01)
• Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-directacting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
  per: Seren M. Gedallovich, et al.
  Publicat: (2024-10-01)
• DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C
  per: Xiaobo Zhu, et al.
  Publicat: (2024-10-01)
• Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication
  per: Natsumi Oe, et al.
  Publicat: (2022-04-01)
• Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan
  per: Chen-Ta Chi, et al.
  Publicat: (2021-06-01)